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Like its better-known polymorphic relatives, HLA-G, a
relatively unpolymorphic class I MHC molecule
expressed by foetal trophoblast cells, binds short
peptides with a defined sequence motif; HLA-G may
play an important role in maternal tolerance to a foetus.
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Sixteen years ago, the cloning of the polymorphic class I
genes of the human major histocompatibility complex
(MHC) — HLA-A, B and C — was driven by a desire to
understand how their products carry out the crucial
immunological function of presenting antigens to cyto-
toxic T cells. The DNA probes thus obtained revealed the
presence in the human genome of a family of class I MHC
genes with at least 15 members in addition to HLA-A, B
and C. Almost immediately, the unfamiliar genes became
a distinct topic of enquiry, creating a subspecialty based
upon ignorance of their associated functions. Within this
niche, the foraging strategy for clues about function is to
compare the properties of the unanticipated genes and
their products with those of HLA-A, B and C and the class
I molecules they encode.
Cloning and sequencing eliminated most of the unantici-
pated HLA genes from further scrutiny, because they were
either incomplete or contained stop codons, frame-shifts
or other defects that would prevent expression of a func-
tional class I protein. Only three genes passed the prelimi-
nary examination [1], and subsequent transfection
experiments demonstrated that these genes — HLA-E, F
and G — are indeed functional, at least as defined by pro-
duction in transfected cells of a class I heavy chain that
associates with b2-microglobulin at the cell surface [2].
Although the initial screen selected for genes similar to
HLA-A, B and C, tangible differences emerged from
further investigation of the successful candidates. 
Unlike HLA-A, B and C, HLA-E, F and G have low poly-
morphism and restricted tissue distribution. One interpre-
tation of these properties is that HLA-E, F and G have
specialized functions related to the immunological require-
ments of the tissues in which they are expressed. This
theme, or variations thereof, provides the working hypoth-
esis for much ongoing research in the field. And at this
juncture, HLA-E, F and G part company, for their tissue
distributions are very different. Most of the limelight has
been captured by HLA-G, the product of which is almost
exclusively found in the extravillous trophoectoderm [3,4],
the tissue of foetal origin that directly contacts the mater-
nal circulation during pregnancy and lacks expression of
HLA-A, B and C (Fig. 1).
In higher mammals, the development of the embryo
within the mother’s body can be seen as an adaptation
which protects the very young from a hostile, unpre-
dictable environment at a time when they are most vul-
nerable. In placental mammals, furthermore, the embryo
and mother are physically connected, facilitating more
efficient communication and disciplined development of
the next generation [5]. This familial intimacy occurs com-
monly in the context of a tissue incompatibility between
mother and young that encompasses an entire MHC
haplotype, a difference that in other circumstances leads
to prompt immunological rejection (‘alloreaction’). The
structure of the placenta and its environment provides the
foetus with protection from the alloreactive tendencies of
the mother. In part this privilege is due to physical barriers
and selective transport mechanisms, but also implicated
Figure 1
The uterus during first trimester, showing the relative positions of cells
expressing HLA-G and HLA-A, B and C. HLA-G is expressed
specifically in the extravillous trophoblasts, cells of foetal origin which
have invaded the maternal tissues of the placenta. Allotypes of the
maternal HLA haplotype inherited by the foetus are designated by m1,
and allotypes of the maternal haplotype not inherited by the foetus by
m2; allotypes of the paternal HLA haplotype inherited by the foetus are
indicated by p1.
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are immunological mechanisms that prevent or suppress
the specific immune response. The latter proposition is
illustrated by the observation that transgenic female mice
expressing T-cell receptors targeted against their mate’s
MHC class I allotype give birth normally and, during
pregnancy, fail to reject subcutaneous tissue grafts of male
type. Subsequent to pregnancy, the alloreactive response
returns and tissue grafts are then rejected [6].
The lack of polymorphic HLA-A, B and C molecules on
extravillous trophoblast probably reduces direct allostimu-
lation of a mother’s cytotoxic T-cell response, while
expression of monomorphic HLA-G may induce T-cell
inactivity in a way perhaps analogous to one of the mecha-
nisms used in generating self tolerance. The presence of
many natural killer (NK) cells in the decidua — the mater-
nal tissue contacting trophoblast cells — invites specula-
tion that HLA-G prevents attack of the trophoblast by
maternal NK cells [7]. NK cells are innately cytotoxic lym-
phocytes which are checked from attacking healthy cells
by interaction of inhibitory receptors with self class I mol-
ecules [8]. NK cells can thus be activated by ‘lack of self’
[9], as illustrated by the NK-cell-mediated rejection of
parental bone marrow by F1 mice [10]. On this principle,
those NK cells that in the mother are inhibited by class I
molecules of the maternal haplotype not inherited by the
foetus have the potential to kill foetal cells and tissues
(Fig. 2). Implicit in the speculation that HLA-G mole-
cules prevent NK cells fulfilling their lethal potential is
the assumption that HLA-G interacts with cytotoxic T
cells and NK cells in a similar manner to HLA-A, B and C.
Consistent with this view are experiments showing HLA-
G binds the T-cell co-receptor CD8 [11] and mediates
inhibition of NK cells [7,12]. Adding further perspective
are recent papers in Current Biology [13] and Immunity [14]
which answer the question that has so often dominated
recent discussions: does HLA-G bind peptide?
The approach taken by both groups was to purify HLA-G
proteins from class I-deficient cells transfected with the
HLA-G gene, for which HLA-G is the predominant class I
species. After denaturation of the HLA-G preparations,
released peptides were collected for study. Complicated
patterns of peaks were seen when the peptides were sepa-
rated by reverse phase high-pressure liquid chromatogra-
phy (HPLC), revealing a heterogeneous pool of peptides,
as is characteristic of most HLA class I isoforms. At this
point, Lee et al. [14] concentrated on determining com-
plete amino-acid sequences for individual peptides within
selected peaks from the HPLC pattern. Twelve of the
thirteen sequences determined corresponded to nonamer
peptides with leucine at the carboxyl terminus (Table 1).
Eleven of the peptides had proline at position 3 and
sequencing the mixed peptide pool revealed additional
selectivity for either arginine or lysine at position 1, and
for hydrophobic residues at positions 2 and 7 (Table 1).
Diehl et al. [13] obtained results consistent with the
binding motif inferred by Lee et al. [14]. They also
sequenced the peptide pool and three individual peptides
extracted from HLA-G (Table 1), and followed this up
with a peptide-binding assay. The results showed that
residues 2, 3 and 9 of the nonamer peptides serve as
‘anchors’ for binding to HLA-G. The anchor residue for
position 2 is either isoleucine or leucine, at position 3 it is
proline, and at position 9 it is leucine. They found some
cross-reactivity between peptide binding to HLA-G and
to HLA-A2. It is clear from these two studies that HLA-G
binds peptides, and that it does so with a similar sequence
specificity to the polymorphic HLA molecules.
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Figure 2
A possible mechanism by which HLA-G of the trophoblast might
protect foetal tissues expressing HLA-A, B and C from attack by
maternal NK cells in the decidua. Two subsets of maternal NK cells are
defined according to whether they are inhibited by HLA-A, B or C
allotypes of one maternal HLA haplotype (m1) or the other (m2).
Maternal cells are equally effective at inhibiting both subsets of NK
cells, whereas foetal cells inhibit only the NK subset with receptors
specific for the m1 haplotype. Foetal cells expressing the paternal
haplotype p1 and just one maternal haplotype (m1 in the diagram),
cannot inhibit NK cells with inhibitory receptors specific for the other
maternal haplotype (m2), and this NK cell subset has the potential to
kill the foetus. HLA-G molecules expressed by the trophoblast cells
separating the mother and foetus are speculated to engage the
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Lee et al. [14] went on to show that, also like the polymor-
phic HLA molecules, cell-surface expression of HLA-G
depends on peptide binding. Transfection with HLA-G of
a cell line lacking the ‘TAP’ transporter, which delivers
peptides to HLA class I molecules in the endoplasmic
reticulum, yielded poor levels of cell-surface expression.
In cells with TAP, however, HLA-G showed a good level
of cell-surface expression and associated transiently with
TAP within the endoplasmic reticulum, in a manner
similar to that reported for other peptide-dependent class
I molecules [15]. In common with transcripts of certain
HLA-A and B alleles, those of HLA-G undergo differential
mRNA splicing to encode a secreted form of the protein
comprising the four extracellular domains, with a similar
conformation to the membrane-bound form. Although
intracellular association of the soluble molecule with TAP
could not be detected, Lee et al. [14] found it binds pre-
cisely the same set of endogenous peptides as the mem-
brane-bound form.
Now we know for sure that HLA-G needs bound peptides
as much as does HLA-A2, the ‘man in the street’ of the
class I allotypes. That the peptide-binding specificity of
HLA-G is neither highly specialized nor outside the distri-
bution defined by HLA-A, B and C can only further the
notion that the extracellular interactions of HLA-G with
other molecules of the immune system are individually
analogous to those of HLA-A, B, and C. However, the
combined effect of such individual interactions might well
be unique; for example, intracellularly, HLA-G has an
unusual vestige of a cytoplasmic tail, a potential source of
difference for the transduction of signals and functional
effects [16]. Overall, the new results reveal the potential
for HLA-G to present diverse peptide antigens at the
mother–foetus interface, and thereby to stimulate immu-
nity against placental infection. An awaiting challenge is
the quest for maternal T cells that respond to HLA-G-
presented peptides. That low levels of HLA-G mRNA
have been detected in thymus (as well as eye, peripheral
blood leukocytes, foetal liver and keratinocytes) certainly
leaves open the possibility that clones of cytotoxic T cells
are positively selected by HLA-G [17].
Mice do not express HLA-G. A pity, because if nature had
been more considerate a knockout mouse with defective
HLA-G genes would have long been made, and its impact
on family values thoroughly explored. All however is not
lost, because Schmidt and Orr [17] have seized the oppor-
tunity to proselytize mice with HLA-G, and see its effects
on their lot. When HLA-G is expressed in transgenic mice
Table 1
Endogenous peptides bound by HLA-G.
Residue number in peptide
Peptide-binding motif 1 2 3 4 5 6 7 8 9 10 11
HLA-A2 L V
M L




Ribosomal protein V L P K L Y V K L
ERP 72 M R P R K A F L L
HLA class III G V P K T H L E L
HSI protein M Q P T H P I R L
Fatty acid synthetase H V P E H A V V L
Unknown S Y P T R I A S L
Ribosomal protein K I A G Y V T H L
Cytokine receptor K G P P A A L T L
Nascent polypeptide K S P A S D T Y I V F
Histone R I I P R H L Q L
Nuclear protein R H P K Y K T E L
Interferon binding R L P D G R V V L
Unknown R L P K D F V D L
Unknown* R L P K D F R I L
Unknown* K L P A Q F Y I L
Unknown* R I I P R H L Q L
In the upper panel, the peptide-binding motifs of HLA-A2 (the A*0201
subtype) and HLA-G are shown. The dominant anchor residues at
positions 3 and 9 are shown in bold. In the lower panel, the sequences
for individual endogenously bound peptides are shown. The peptides
sequenced by Diehl et al. [13] are indicated by an asterisk (*); all others
were determined by Lee et al. [14]. Note that these peptides are those
that HLA-G captures with greatest abundance when expressed in
Epstein–Barr virus transformed B cells. Although the peptide-binding
motif of HLA-G expressed by trophoblast cells is unlikely to change, the
repertoire of individual peptides bound may well exhibit differences.
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from the HLA-A2 promoter, its properties resemble those
of a conventional class I molecule recognized by the
receptors of cytotoxic T cells. Thus, HLA-G transgenic
skin is rejected by non-transgenic mice, but not by trans-
genic mice. Such results reaffirm the doctrine that HLA-G
is a covert run-of-the-mill antigen-presenting molecule.
Setting the stage for future revelations is the fact that,
when under the control of its own promoter in transgenic
mice, HLA-G is expressed in a pattern similar to that of the
endogenous gene in humans.
That mice have managed without it for some time (~80
million years) would seem to argue that HLA-G does not
have a housekeeping function in the biology of placental
mammals. Thus, the benefits of having HLA-G might well
be subtle, perhaps comparable to those conferred by
heterozygosity at the HLA-A, B or C loci, and the possible
benefits to mice may only be revealed by experiments in
which populations of HLA-G transgenic and non-trans-
genic animals are uncaged and pitted one against another.
On the human front, a survey of HLA-G alleles in African-
Americans reveals a previously unsuspected level of poly-
morphism, and the presence of certain alleles expected to
be non-functional [18]. Further assessment of the impor-
tance of HLA-G could come from expanded study of
human populations to determine the frequency of
homozygotes for such null HLA-G alleles.
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